title: Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
abstract: For the improvement of chemotherapy with platinum (Pt)-containing drugs a sensitive assay to detect the induced Pt-DNA adducts is needed. Therefore, the 32P-postlabelling assay, described by Blommaert and Saris (Nucleic Acids Res., 1995, 23, 1300-1306), to detect the major adducts Pt-GG and Pt-AG has substantially been improved and compared with ELISA and AAS. For the quantification of the adducts, TpT was added as an internal standard immediately after isolation of the Pt-adducts from digested DNA samples. It was found that 32P-labelling of both GpG and ApG, the dinucleotides obtained after deplatination of the adducts, was equally efficient as that of TpT. To isolate the Pt-adducts on basis of a positive charge, the pH of DNA digests was adjusted to approximately 3 prior to separation by strong cation-exchange chromatography. For the subsequent deplatination a volume of only 12 microl of 0.2 M NaCN was used, which did not interfere with the following labelling step. The quantification of the 32P-labelled dinucleotides was performed by phosphorimaging of spots after separation on TLC as well as by 32P-counting of fractions collected after separation by HPLC. The method was used to determine adduct levels in in vitro cisplatin-treated DNA and in DNA isolated from cisplatin-treated cultured cells, tumor xenografts from cisplatin-treated mice, and from white blood cells and (tumor) tissues from cisplatin-treated patients. The results show a significant correlation with the adduct levels as determined with atomic absorption spectroscopy (high levels) or with specific antibodies (low levels). This assay appears to be useful for the determination of low levels of Pt-adducts in small DNA samples as present in clinical specimens such as blood and tumor tissue, but also in buccal mucosal cells and fine needle aspirates.
authors.affiliation: Toxicology Division, TNO Nutrition and Food Research Institute, Zeist, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Welters
authors.forename: M
authors.initials: M
authors.lastname: Maliepaard
authors.forename: A J
authors.initials: AJ
authors.lastname: Jacobs-Bergmans
authors.forename: R A
authors.initials: RA
authors.lastname: Baan
authors.forename: J H
authors.initials: JH
authors.lastname: Schellens
authors.forename: J
authors.initials: J
authors.lastname: Ma
authors.forename: W J
authors.initials: WJ
authors.lastname: van der Vijgh
authors.forename: B J
authors.initials: BJ
authors.lastname: Braakhuis
authors.forename: A M
authors.initials: AM
authors.lastname: Fichtinger-Schepman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D002945:Cisplatin / Q000032:analysis* / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000187:drug effects*; D018736:DNA Adducts / Q000032:analysis*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D051379:Mice; D010761:Phosphorus Radioisotopes; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D010761:Phosphorus Radioisotopes; C057270:cisplatin-DNA adduct; D004247:DNA; D002945:Cisplatin